October 03, 2024 – ETCTN
CTEP is accepting LOIs to conduct clinical studies using Camonsertib, an oral ataxia telangiectasia and Rad3-related (ATR) inhibitor (ATRi), which is being developed by CTEP as an anticancer agent in collaboration with…
DF/HCC Is a Research Consortium
that provides shared resources and a collaborative environment for over 1,100 cancer researchers at 7 Harvard institutions. Learn more about DF/HCC here
Information for DF/HCC members and collaborators
Shared resources available to DF/HCC members
Resources and initiatives for Massachusetts communities
Opportunities for training and career enhancement